; on behalf of the ASTER Trial Investigators Abstract Rationale: Mechanical thrombectomy with a stent retriever is now the standard of care in anterior circulation ischemic stroke caused by large vessel occlusion. New techniques for mechanical thrombectomy, such as contact aspiration, appear promising to increase reperfusion status and improve clinical outcome.
Introduction and rationale
Endovascular recanalization therapies for patients with acute ischemic stroke (AIS) and large vessel occlusion with second-generation (primarily stent retrievers (SRs) have included have been demonstrated to be beneficial across six large randomized clinical trials.
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Mechanical thrombectomy strategy
Recanalization rate is a major issue given that favorable clinical outcome after AIS is strongly correlated with successful recanalization. 6, 7 The addition of endovascular thrombectomy to standard medical care also resulted in better 24-h recanalization rates (71% of successful recanalization rate). 5 In these five RCTs, mechanical thrombectomy was performed in more than 80% of cases with a stent retriever (SR), a selfexpanding stent used to retrieve thrombi. 8 European and American recommendations propose conducting clinical trials to determine the best thrombectomy device in order to increase the recanalization rate. [1] [2] [3] [4] A novel thrombectomy technique-''a direct aspiration first pass technique'' (ADAPT) or contact aspiration (CA) technique-involves the first-line use of aspiration through a large-bore catheter. [9] [10] [11] [12] [13] CA is an approach that utilizes the advantages of large-bore aspiration catheters that can be easily tracked and introduced into the cerebral circulation to directly remove the thrombus via negative pressure aspiration. If this aspiration is not directly effective, it maintains the thrombus engaged in the catheter tip through suction and the clot is removed as the catheter is withdrawn. In the minority of cases where aspiration is not successful in removing the blockage, the large aspiration catheter provides access to direct an SR to the thrombus site (versatile technique).
Various studies have reported revascularization rates of 65-78% with CA alone, which rises to 82-100% for CA followed by further endovascular treatment (e.g. SR). Ninety-day mRS 0-2 scores have been reported for 40-56% of patients treated with CA (with or without further treatment). 9, 11, 12, 14, 15 There are, however, few medico-economic evaluation studies comparing the effectiveness of mechanical thrombectomy strategies in the treatment of cerebral infarction. A retrospective study suggests that the CA strategy engaged a lower device cost than the SR as a first-line therapy approach. 16, 17 The ASTER trial aims to compare the efficacy and safety of first-line neurothrombectomy using the CA technique versus the standard SR technique. A costefficiency analysis (ASTER-ECO) will be performed.
Methods
Design
The ASTER trial is a prospective, randomized, multicenter, controlled, open-label, blinded endpoint (PROBE) clinical trial. It is an academic trial designed to answer the question ''What is the best first-line strategy of mechanical thrombectomy (CA or SR) to obtain the best reperfusion rate ate the end of the endovascular procedure?'' Patients will be recruited at eight high-volume, comprehensive stroke centers in France, all of which regularly conduct both types of technique. The study, which is registered with ClinicalTrials.gov (Identifier NCT02523261), will be conducted in accordance with the Declaration of Helsinki and Good Clinical Practice. Data collection during the study is reported in Table 1 and carried out using an electronic case report form (eCRF), developed using Clinsight software (Publisher ENNOV).
Patient population
This study will enroll adults admitted with suspected ischemic stroke secondary to large vessel occlusion of the anterior circulation, within 6 h of the onset of symptoms ( Figure 1 ). Inclusion and exclusion criteria are detailed in Table 2 . Informed consent according to the French laws will be sought from the patient-if their level of consciousness is sufficient-or from a relative. This study will operate using an emergency inclusion protocol due to the nature of the condition. However, patients can request to be removed from the study at any point. These collected data will be destroyed.
Randomization
Immediately after baseline brain imaging and prior to endovascular procedure, patients are randomly allocated in a one-to-one ratio to receive either the CA (experimental) or the SR (control) technique as the first-line endovascular intervention using a web-based central randomization. The randomization sequence is provided by an independent statistician (who will not take part in assessing the patients at any point in the study) using computer-generated random numbers with blocks sizes of four and stratification on center and prior use of IV thrombolysis. The randomization sequence is implemented in the eCRF system to assure a centralized real time randomization procedure. Patients are enrolled and randomized by vascular neurologists and interventional neuroradiologists.
Interventions
In line with the recommendations of the American Stroke Association and European Stroke Organization, 3, 18 the patients having undergone acute proximal artery occlusion within the last 6 h will be given IV thrombolysis (if they are eligible) and will be transferred fast to the cat lab if they fulfill the inclusion criteria and have no exclusion criteria of the study protocol. After endovascular treatment, the patients will be transferred to acute stroke unit and received normal high-quality care.
Patients will undergo their assigned endovascular procedure (CA or SR) under general anesthesia or conscious sedation. Both these techniques will be conducted in accordance with good practice recommendations (maximum of three attempts before switching to another strategy; use of a proximal occlusion balloon with the SR).
Once the patient is randomly assigned to undergo CA or SR mechanical thrombectomy, the time between International Journal of Stroke, 13 (1) randomization and the endovascular procedure should be as shorter as possible.
An introducer sheath will be placed in the femoral artery. Diagnostic angiography is initially performed via the transfemoral approach with catheterization of the carotid artery appropriate to the patient's presenting symptoms. After the thrombus in the appropriate vessel is identified, the thrombectomy procedure will be initiated.
As per local standard of care and prior to the thrombectomy, a digital subtraction angiography (DSA) will be performed to define the angiographic architecture of the occluded vascular segment. Whether possible, an assessment of collateral blood flow by DSA should be made as per the institutional standard of care, particularly in cases of terminal internal carotid artery occlusion. Prior to mechanical thrombectomy by the thrombectomy device, baseline modified Thrombolysis in Cerebral Infarction (mTICI) and artery occlusion lesion (AOL) scores by DSA will be obtained.
CA technique
The CA approach is performed using a long sheath positioned in the distal cervical vasculature using an exchange technique. The technique has been previously reported. 9, 11, 13, 19, 20 A 0.021 to 0.027 in. inner lumen microcatheter, with a 0.014 to 0.016 in. microwire inside, is then introduced into a large-bore aspiration catheter, and this construct is introduced into the long sheath as a unit. The microcatheter is then advanced past the thrombus over the microwire and the largebore aspiration catheter is advanced as close to the proximal aspect of the thrombus as possible. A control superselective angiogram may be used to document the extent of vascular occlusion by thrombus. Then the large-bore aspiration catheter is connected to a source of continuous aspiration. This process is repeated until successful reperfusion (thrombolysis in cerebral infarction (TICI) 2b/3) is achieved or the procedure terminated. At least three attempts must be made before performing a rescue therapy using another technique. Operators are encouraged to perform at least three passes before changing endovascular procedure strategy but this is left to their discretion. The choice of this rescue technique will be left to the discretion of the operator.
SR technique
The technique used should be in accordance with the device IFU. A large bore balloon guide catheter is International Journal of Stroke, 13 (1) placed first in the cervical ICA. A suitable delivery microcatheter is navigated over a microwire into the occluded intracranial ICA or MCA and across the occlusion. A control superselective angiogram may be used to document the extent of vascular occlusion by thrombus. Any CE-marked SR device is then deployed across the occlusion. Removal should occur with proximal occlusion by inflation of the balloon guide catheter. A minimum of three attempts with SR should be performed before changing to a rescue therapy using another technique. Operators are encouraged to perform at least three passes before changing endovascular procedure strategy but this is left to their discretion. A revascularization score will be recorded after each device attempt. The choice of the rescue technique will be left to the discretion of the operator.
The use of balloon guide catheter (BGC) is mandatory during the ASTER TRIAL in the stent retriever arm.
This is based on retrospective data which argue on favor to the use of BGC during SR technique. 23 The choice of the device was left to the discretion of the operator. All of the FDA-or CE-marked cerebral aspiration catheter and SR thrombectomy devices are allowed in the study All of the participating comprehensive stroke centers in ASTER Trial performed more than 100 thrombectomy per year (high volume CSC).
All of the operators have performed more than 10 endovascular procedures with SR and CA techniques.
Outcomes
Primary outcome. The primary outcome is the percentage of patients with successful recanalization defined as a modified Thrombolysis in Cerebral Infarction (mTICI) score of 2b (perfusion !50% of the vascular distribution of the occluded artery]) or 3 (full perfusion with filling of all distal branches) 22 ) at the end of angiography done after the endovascular treatment (i.e. after the assigned treatment and any further treatment deemed necessary).
Secondary outcomes. The secondary technical efficacy outcomes are the percentage of patients with successful recanalization (mTICI 2b-3, 2B, 2c-3, and 3 separately) at the end of the assigned first-line endovascular treatment (CA vs. SR alone) and the times from femoral puncture to successful recanalization (TICI 2b-3) at the end of the first-line strategy and at the end of angiography.
The secondary clinical efficacy outcomes are the global disability assessed by overall distribution of the modified Rankin scale (mRs) at 90 days (shift analysis combining scores of 5 and 6), 23 the functional independence as defined by a 90-day mRs 2, the change in National Institute of Health Stroke Score (NIHSS) score at 24 h, and the percentage of deaths due to any cause at 90 days.
Study safety outcomes are procedure-related serious adverse events (arterial perforation, arterial dissection, subarachnoid hemorrhage, embolization in a new territory), intracranial hemorrhage on brain imaging at 24 AE 12 h (according to the European Cooperative Acute Stroke Study (ECASS)2 classification), symptomatic intracranial hemorrhage at 24 h (any ICH visualized on follow-up imaging study and associated with a 4 or more point worsening on the NIHSS score or that resulted in death (causal relationship).
Lastly, the cost-effectiveness of the two procedures will be analyzed. Two points of view will be adopted: the hospital's point of view and that of Medicare.
The average cost per patient with complete recanalization will be assessed. For each subject, device costs (the market price for all devices used) will be collected for the hospitalization during which the index procedure took place. These costs will include device costs, materials used to treat the occlusion, and number of days spent in the hospital (ICU and non-ICU length of stay). We estimated the average cost of a gain in autonomy for each patient and/or the average cost of a loss of autonomy for each patient at three months and the costs per quality-adjusted life year (QALY).
Blinding
Regarding the primary end-point, first, a central invasive imaging core lab, not involved in the trial patient management, will record the mTICI score, collaterality status, and periprocedural complications. In cases of disagreement between the two assessors, a centralized neurointerventionalist will review angiograms and decide on the primary end-point value. All neuroimaging secondary end-points (in CT or MR images) including sites of arterial occlusion, clot burden score, recanalization at 24 h, infarct volume and hemorrhage, will be determined by the CT/MR non-invasive imaging core-lab, which also will be blinded to treatment allocation. Serious adverse events (SAEs) and procedure-related complications will be adjudicated by three members of the Data Safety Monitoring Board (DSMB) that will be blinded to the treatment arm. The mRS score at 90 days will be assessed by trained research nurses unaware of the study group assignments, during face-to-face interviews or via telephone conversations.
Independent DSMB
The purpose of the DSMB is to review the unmasked accumulated safety data. The DSMB will be composed of three stroke neurologists or interventionalists International Journal of Stroke, 13 (1) (at least one of each), who are not participating in the study and are not affiliated with the sponsor. The role of the DSMB will be to review the occurrence of AEs, and it will ensure the balance of complication rates between arms throughout the study by making recommendations to the Executive Committee regarding safety aspects.
Sample size estimates
On the basis of the pooled individual data analysis from five RCTs 24 and our previous observational study, 12 we expected a rate of successful recanalization of 70% in patients treated with standard SRs as first-line mechanical thrombectomy (control group). Based on published data on CA, 11, 13, 14, 25 we assumed that the use of CA as the first-line method of mechanical thrombectomy (experimental group) could increase this rate to 85% (i.e. an absolute and relative risk reduction of 15% and 21%, respectively). To detect this effect size, with a two-sided test, at an alpha level of 5%, and a power of 90%, 161 patients would be required per group. To account for an anticipated rate of spontaneous recanalization and catheterization failures of 15%, 26 we planned to include a total of 380 patients (190 per group).
Statistical analyses
Statistical analyses will be independently performed by the Biostatistics Department of Lille University; for data analysis, statisticians and investigators will be aware of the treatment group allocation. Data will be analyzed using SAS software (SAS Institute Inc., Cary, NC, USA), and all statistical tests will be performed with a two-tailed alpha risk of 0.05. Baseline characteristics will be described for each treatment group; categorical variables will be expressed as frequencies and percentages and quantitative variables will be expressed as means AE standard deviation or medians (interquartile range) for non-Gaussian distribution. Normality of distributions will be assessed graphically and by using the Shapiro-Wilk test. All analyses will be performed in all randomized patients based on their original group of randomization, according to the intention-to-treat principle. The final report will be written, based on the CONSORT statement recommendations.
Primary outcome. The study was designed to have a statistical power of 90% with a two-sided alpha level of 0.05 to show the superiority of the CA over the standard SRs as the first-line method of endovascular procedure, to achieve successful reperfusion (mTICI 2b/3) at the end of the procedure (primary efficacy outcome).
The percentage of cases of successful recanalization achieved at the end of the endovascular procedure will be calculated and compared between the two treatment groups using a mixed logistic regression model including treatment groups and prior use of IV thrombolysis as fixed effects and center as a random effect. Adjusted odds ratio (OR) will be derived from this model as the treatment effect size (CA relative to SR). Using the method described by Austin, 27 the numbers needed to treat absolute and relative risk differences will be derived from the marginal probabilities of success. Since we expected no missing data on primary outcome, no imputation procedure will be applied. In cases of catheterization failure, primary outcome will be considered as unsuccessful whatever the treatment group. A sensitivity analysis will be conducted in per protocol population defined as all patients who received the assigned frontline endovascular treatment (CA or SR) with at least three attempts to obtain a successful recanalization.
As exploratory analyses, heterogeneity in treatment effect size on primary outcome across key subgroups will be evaluated by including the corresponding multiplicative interaction terms in the multivariate mixed logistic regression models. From these models, treatment effect sizes (adjusted OR) will be estimated in each subgroup. The following key subgroups will be investigated:
. Prior use of IV thrombolysis (yes vs. no) . Baseline site of thrombi on vascular imaging (ICA, M1, M2) . Clot Burden score (<6 vs. !6) Secondary outcomes. Secondary binary outcomes will be also analyzed using a mixed logistic regression model including treatment groups and prior use of IV thrombolysis as fixed effects and center as a random effect; adjusted ORs will be calculated as the treatment effect size. For procedure-related serious AEs, only the rate of patients with at least one AE will be compared between the two groups (based on subject counts and not on event counts). The rate of specific AEs will be evaluated descriptively with their exact 95% confidence intervals. The secondary ordinal outcome (distribution of 90-day mRs, after combining scores of 5 and 6) will be analyzed using a mixed ordinal logistic regression model including treatment groups and prior use of IV thrombolysis as fixed effects and center as a random effect; adjusted common OR will be calculated as the treatment effect size. The secondary quantitative outcome (change in NIHSS score at 24 h) will be analyzed using the constrained longitudinal data analysis (cLDA) model proposed by Liang and Zeger. This model will be used in view of the potential advantages of the cLDA compared to the conventional longitudinal analysis of covariance (ANCOVA) model. 29 In the cLDA, both the baseline and post-baseline values are modeled as dependent variables using a linear mixed model (using an unstructured covariance pattern model), and the true baseline means are constrained to be the same for the two treatment groups. Hence, the cLDA provides an adjustment for the observed baseline difference in estimating the treatment effects, using all available baseline and post-baseline values. The between-group mean differences in 24-h change in NIHSS will be estimated by the time-byarm interaction as treatment effect size. If normality of model residuals are not satisfied, non-parametric analysis will be used; absolute changes between baseline and 24 h will be calculated and compared between the two treatment groups using non-parametric analysis of covariance adjusted for baseline values. Discussion ASTER Trial will be the first RCT with PROBE design, which has been designed to assess the best front line strategy of mechanical thrombectomy between CA and SR in acute ischemic stroke. The primary outcome for this study will be the difference in revascularization rates at the end of the procedure(s) in patients randomized to CA or SR. Revascularization rate was chosen as the primary outcome because it is a major early indicator of treatment success, has been correlated with good clinical outcome, 7, 22 and has been used as a primary outcome in other stroke trials comparing thrombectomy devices, e.g. SWIFT 32 and TREVO2 33 -which compared stent or stent-like retrievers with mechanical thrombectomy. In these studies, 32,33 revascularization rates were compared just after the assigned procedure. However, we chose primarily to compare recanalization rates after all procedure(s) (final angiogram) had been completed. Indeed, the ASTER trial was designed to assess the impact of CA or SR in first-line endovascular strategy on the entire procedure and not to directly compare the CA and SR techniques used alone. We hypothesized that first-line CA strategy would increase successful recanalization rate and decrease the procedural time.
30,31
Study organization and funding
We chose to define revascularization as mTICI 2b-3 (2b ¼ !1/2 perfusion; 3 ¼ full perfusion 22 ). This modified version was used rather than the original TICI (2a ¼ <2/3 partial filling; 2b ¼ complete, but slow, filling; 3 ¼ complete filling 34 ) because mTICI has been reported to be a better predictor of clinical outcome 7, 35 and it is easier to estimate 1/2 than 2/3. However, new evidence indicates that the achievement of TICI 3 results in better clinical outcomes than TICI 2b. 7, 36 CA could result in a higher rate of mTICI 3 than SRs because SRs have to be passed through the clot, and could therefore result in a higher rate of distal erratic emboli, as it has been emphasized in in vitro studies. 37 Secondary outcomes include time to revascularization (as this has been correlated with clinical outcome, 6 NIHSS score at 24 hours (indicating early neurological improvement), and actual disability at 90 days (mRS 0-2 and ordinal analysis). Improved 90-day disability score is an important endpoint for patients and has been used as a primary outcome in many stroke trials, e.g. ESCAPE 24 and SWIFT PRIME. 8 We will also undertake an economic analysis (ASTER ECO), as thrombectomy is an expensive technique, so any cost savings with CA would be beneficial. CA has been found to result in lower mean total hospitalization costs than SR with local aspiration in a single-center retrospective review of 222 patients. 16 
Summary and conclusions
No previous head to head randomized trials have directly compared CA versus SR reperfusion techniques. This prospective trial aims to provide further evidence of benefit of CA versus SR techniques among patients with ischemic stroke secondary to major occlusion of the anterior circulation.
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